Pneumocystis Primary Infection in Non-immunosuppressed Infants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-21

Study Completion Date

2021-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the prevalence of P. jirovecii in nasopharyngeal aspirations of neonates and infants hospitalized for symptomatic respiratory infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non Invasive Diagnosis of Pneumocystis Pneumonia

NCT03613025

Pneumocystis

COMPLETED NA

Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.

NCT05060146

Streptococcus Pneumoniae Infection

COMPLETED NA

Streptococcus Pneumoniae Nasopharyngeal Carriage

NCT01485029

Nursery

UNKNOWN NA

Birth Cohort Study for Respiratory Infections

NCT02361164

Upper Respiratory Tract Infections

COMPLETED

Pneumococcal Carriage in Patients With Lower Respiratory Tract Infection (LRTI)

NCT01861184

Lower Respiratory Tract Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is recognized that primary infection with Pneumocystis, an opportunistic and transmissible fungus, occurs early in childhood. Early investigations of primary infection considering the detection of P. jirovecii in respiratory specimens suggests that primary infection in infants without immunodeficiency could be either asymptomatic or symptomatic. The infection may be identified as an apparently benign respiratory infection evolving on its own, but may also be contemporaneous with another viral or bacterial respiratory infection. In addition, there are little data available on the genotypic characteristics of P. jirovecii in infants developing primary infection.

In this context, the project will focus on the detection of P. jirovecii in hospitalized infants, presented with symptoms, and without overt immunodeficiency. The prospective collection of biological, clinical and epidemiological data in these infants will make it possible to identify risk factors for the acquisition of the fungus and to address its role in symptoms and clinical presentation. A second focus will be on the identification and comparison of genotypes in infants developing primary infection and in immunocompromised adults developing PPC or colonized by the fungus. These two approaches are the necessary steps to address the putative role of these patient populations (infants and adults) in the human reservoir of the fungus. A third focus will be the detection and genotypic identification of P. jirovecii in infants and the exhaled air of infants in their environment. The potential role of infants as potential infectious sources may be determined.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Diseases Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* symptomatic newborns and infants who underwent NPAs for microbiological diagnoses

Exclusion Criteria

* asymptomatic newborns and infants, newborns and infants who did not undergo NPAs, infants \> 12 months or children \> 2 years; newborns and infants whose parents did not accept to participate

Maximum Eligible Age

12 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No